Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Stage IV Non-Small Cell Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT01131429
What this trial is testing

A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations

Who this might be right for
Neoplasms, LungCarcinoma, Non-Small Cell LungDrug Therapy+1 more
Chinese PLA General Hospital 60
Testing effectiveness (Phase 2)Study completedNCT01737502
What this trial is testing

Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer

Who this might be right for
Extensive Stage Small Cell Lung CarcinomaLung AdenocarcinomaRecurrent Non-Small Cell Lung Carcinoma+5 more
Mayo Clinic 29
Testing effectiveness (Phase 2)Study completedNCT00387322
What this trial is testing

Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

Who this might be right for
Lung CancerUnspecified Adult Solid Tumor, Protocol Specific
University of California, Davis 42
Large-scale testing (Phase 3)Study completedNCT01257139
What this trial is testing

Trial Involving Subjects Over 70 Years of Age With Non Small-cell Lung Cancer of Stage IV and Comparing a "Classical" Strategy of Treatment Allocation, With an"Optimized" Strategy Allocating the Same Treatments

Who this might be right for
Non Small-cell Lung Cancer
Rennes University Hospital 490
Testing effectiveness (Phase 2)Looking for participantsNCT05950139
What this trial is testing

Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

Who this might be right for
NSCLC Stage IVALK Fusion Protein Expression
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 12
Early research (Phase 1)UnknownNCT00497250
What this trial is testing

Phase I Study of Iressa and CRT/IMRT in Chinese Patients With IIIB/IV NSCLC After Failure of Platinum-Based Chemotherapy

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Fudan University 32
Testing effectiveness (Phase 2)UnknownNCT03647956
What this trial is testing

Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

Who this might be right for
NSCLC Stage IIIBNSCLC Stage IVEGFR Activating Mutation
The University of Hong Kong 40
Large-scale testing (Phase 3)Study completedNCT00349102
What this trial is testing

Prevention of Radiation Pneumonitis After Three-dimensional Conformal Radiation Therapy (3D-CRT) in Patients With Non-small-cell Lung Cancer

Who this might be right for
Carcinoma, Non-small-cell Lung
Centre Leon Berard 242
Testing effectiveness (Phase 2)Study completedNCT04623775
What this trial is testing

Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung CancerRecurrent Non-small Cell Lung CancerMetastatic Non-small Cell Lung Cancer
Bristol-Myers Squibb 468
Large-scale testing (Phase 3)Study completedNCT02713867
What this trial is testing

A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Who this might be right for
Lung Cancer
Bristol-Myers Squibb 363
Early research (Phase 1)Study completedNCT01014598
What this trial is testing

Cisplatin in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer or Lung Metastasis

Who this might be right for
Metastatic Malignant Neoplasm in the LungStage IIIB Non-Small Cell Lung CancerStage IV Adult Soft Tissue Sarcoma+1 more
Roswell Park Cancer Institute 11
Not applicableStudy completedNCT04009122
What this trial is testing

Evaluation of the Quality of Life of Patients With Metastatic Non-small Cell Lung Cancer With Supplementary Therapy With IGEN-0206

Who this might be right for
Quality of Life of PatientsNon-small Cell Lung Cancer Metastatic
Igen BioLab SLU 266
Large-scale testing (Phase 3)Ended earlyNCT03515629
What this trial is testing

REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Regeneron Pharmaceuticals 5
Testing effectiveness (Phase 2)Ended earlyNCT04933695
What this trial is testing

Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment

Who this might be right for
Non-small Cell Lung Cancer
Amgen 42
Testing effectiveness (Phase 2)Study completedNCT01139775
What this trial is testing

A Study in Non Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Eli Lilly and Company 76
Large-scale testing (Phase 3)UnknownNCT02076477
What this trial is testing

The Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer（NSCLC）

Who this might be right for
Oligo-metastatic Stage IV Non-small Cell Lung Cancer
Sichuan Cancer Hospital and Research Institute 420
Not applicableStudy completedNCT01004601
What this trial is testing

Low Dose Weekly Docetaxel Versus Pemetrexed in Previously Treated Advanced Non-Small-Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Chang Gung Memorial Hospital 179
Not applicableNot Yet RecruitingNCT07689812
What this trial is testing

Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)NSCLC (Non-small Cell Lung Cancer)NSCLC (Non-small Cell Lung Carcinoma)+12 more
Natera, Inc. 920
Testing effectiveness (Phase 2)Ended earlyNCT00592007
What this trial is testing

Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Carcinoma
Lyudmila Bazhenova, M.D. 7
Testing effectiveness (Phase 2)Study completedNCT01107444
What this trial is testing

Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Eli Lilly and Company 180
Next Page